The PTCTC Cellular Therapy Strategy Group seeks to discuss and design novel multicenter trials using cellular therapy, and the toxicities, logistics, and financial implications of their use.  These include immune effector cells such as T cells and natural killer cells, either alone or redirected to targets using chimeric antigen receptors (CARs) or bispecific antibodies directed at tumor antigens or autoreactive lymphocytes.

Other cellular therapy approaches such as viral specific T cells or regulatory T cells may be directed at transplant complications such as infections or graft vs. host disease, or mesenchymal stem cells or innate lymphoid cells to facilitate tissue repair following transplantation. Effector cell sources may be autologous, donor-derived, or 3rd party, and may be given prior to (to achieve remission), during (preventive), or after (maintenance or disease control) transplantation, or for treatment of autoimmune disease.

Chair